NCT06978933View on ClinicalTrials.gov

FGF19 Overexpression Combination Unified Study in HCC-19

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
HCC - Hepatocellular Carcinoma
Interventions
DRUG

ABSK-011

"Drug: ABSK-011 RP2D according to the results of Phase I trial~Other Names:~• FGFR4 inhibitor Drug: ABSK043 RP2D according to the results of Phase I trial~Other Names:~• Oral PD-L1 inhibitor"

Trial Locations (1)

Unknown

RECRUITING

Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER